Nathaniel Aleynick
Memorial Sloan Kettering Cancer Center
4 Papers
Nathaniel Aleynick is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.
Bin Xu,Achim A. Jungbluth,Denise Frosina,Bayan Alzumaili,Nathaniel Aleynick,Elzbieta Slodkowska,Kevin Higgins,Alan L. Ho,Luc G. T. Morris,Ronald Ghossein,Nora Katabi +10 more
TL;DR: Cancer testis antigens, e.g. preferentially expressed antigen in melanoma (PRAME), are regarded as promising vaccine targets because of their tumour‐specific expression pattern.
51
Cross-platform dataset of multiplex fluorescent cellular object image annotations
Nathaniel Aleynick,Yanyun Li,Yubin Xie,Mian Zhang,Lev Roshal,Dana Pe'er,Rami Vanguri,Travis J. Hollmann +7 more
TL;DR: In this paper , the authors released 105,774 primarily oncological cellular annotations concentrating on tumor and immune cells using over 40 antibody markers spanning three fluorescent imaging platforms, over a dozen tissue types and across various cellular morphologies.
Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis.
Arielle Elkrief,Natalie Smith,John B. Slingerland,Nathaniel Aleynick,Melissa Lumish,Paul A Giardina,Jamie E. Chaft,Paul B. Chapman,Juliana Eng,Robert J. Motzer,Robin B. Mendelsohn,Marcel R.M. van den Brink,Jinru Shia,Susan DeWolf,Matthew D. Hellmann,Jonathan U. Peled,David Faleck +16 more
TL;DR: In this paper , the authors used whole metagenomic shotgun sequencing (WMS) to profile the faecal microbiota profiles from N = 18 patients with immune-related colitis and described their clinical experience of N = 5 patients treated with healthy donor fecal microbial transplantation (FMT).
3
Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features
Bin Xu,Ed Reznik,R. Michael Tuttle,Jeffrey A. Knauf,James A. Fagin,Nora Katabi,Snjezana Dogan,Nathaniel Aleynick,Venkatraman E. Seshan,Sumit Middha,Danny Enepekides,Gian Piero Casadei,Erica Solaroli,Giovanni Tallini,Ronald Ghossein,Ian Ganly +15 more
TL;DR: Oncocytic NI-EFVPTC, when stringently selected for, lacks metastasis at presentation and follows an extremely indolent clinical course, even when treated conservatively with lobectomy alone without RAI therapy.